These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 18199556

  • 1. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB.
    Cancer Res; 2008 Jan 15; 68(2):589-96. PubMed ID: 18199556
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T, Lowell AM, Engelman JA, Shapiro GI.
    Cancer Res; 2005 Jul 15; 65(14):6401-8. PubMed ID: 16024644
    [Abstract] [Full Text] [Related]

  • 3. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.
    J Thorac Oncol; 2012 Jul 15; 7(7):1078-85. PubMed ID: 22592212
    [Abstract] [Full Text] [Related]

  • 4. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.
    Lung Cancer; 2012 Feb 15; 75(2):161-6. PubMed ID: 21767894
    [Abstract] [Full Text] [Related]

  • 5. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 15; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 6. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, Solit DB.
    Clin Cancer Res; 2008 Jan 01; 14(1):240-8. PubMed ID: 18172276
    [Abstract] [Full Text] [Related]

  • 7. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.
    Regul Toxicol Pharmacol; 2012 Dec 01; 64(3):415-24. PubMed ID: 23069143
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N.
    Cancer Res; 2003 May 01; 63(9):2139-44. PubMed ID: 12727831
    [Abstract] [Full Text] [Related]

  • 9. Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
    Sudo M, Chin TM, Mori S, Doan NB, Said JW, Akashi M, Koeffler HP.
    Cancer Chemother Pharmacol; 2013 May 01; 71(5):1325-34. PubMed ID: 23515752
    [Abstract] [Full Text] [Related]

  • 10. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N.
    Clin Cancer Res; 2002 May 01; 8(5):986-93. PubMed ID: 12006510
    [Abstract] [Full Text] [Related]

  • 11. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2013 Oct 01; 104(10):1346-52. PubMed ID: 23863134
    [Abstract] [Full Text] [Related]

  • 12. [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
 being resistant to EGFR-TKI].
    Zhao L, Cao F.
    Zhongguo Fei Ai Za Zhi; 2014 Nov 01; 17(11):778-82. PubMed ID: 25404267
    [Abstract] [Full Text] [Related]

  • 13. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
    Hong YS, Jang WJ, Chun KS, Jeong CH.
    Oncol Rep; 2014 Jun 01; 31(6):2619-24. PubMed ID: 24789511
    [Abstract] [Full Text] [Related]

  • 14. Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
    Regales L, Balak MN, Gong Y, Politi K, Sawai A, Le C, Koutcher JA, Solit DB, Rosen N, Zakowski MF, Pao W.
    PLoS One; 2007 Aug 29; 2(8):e810. PubMed ID: 17726540
    [Abstract] [Full Text] [Related]

  • 15. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.
    PLoS One; 2016 Aug 29; 11(3):e0150567. PubMed ID: 26962872
    [Abstract] [Full Text] [Related]

  • 16. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
    Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI.
    Clin Cancer Res; 2012 Sep 15; 18(18):4973-85. PubMed ID: 22806877
    [Abstract] [Full Text] [Related]

  • 17. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.
    Anticancer Res; 2019 Apr 15; 39(4):1767-1775. PubMed ID: 30952716
    [Abstract] [Full Text] [Related]

  • 18. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S, Qu X, Li W, Zhong X, Li P, Yang S, Chen X, Shao M, Zhang L.
    J Hematol Oncol; 2015 Apr 29; 8():43. PubMed ID: 25925741
    [Abstract] [Full Text] [Related]

  • 19. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, Shi R, Liu M, Liu C, Chen C, Liu H, Chen J.
    BMC Cancer; 2020 Dec 04; 20(1):1189. PubMed ID: 33276757
    [Abstract] [Full Text] [Related]

  • 20. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA.
    J Surg Res; 2012 Jul 04; 176(1):147-53. PubMed ID: 22099584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.